These findings suggest a new role for mTORC1–SRPK2 signaling in the posttranscriptional regulation of lipid metabolism and highlight SRPK2 as a promising therapeutic target for metabolic disorders driven by mTORC1. The gene discussed is SRPK2; the disease is Other metabolic disease.